Clinical Cancer Research · 2020 · 45 citations · 28 references
MedicineOncologyPharmacologyChemotherapyPediatric Clinical PharmacologyPediatric OncologyChemotherapy ResistanceChemotherapy Toxicity ManagementPediatric ChemotherapyPediatric Clinical TrialsPediatric LeukemiasRefractory Childhood CancerAcute Lymphoblastic Leukemia TherapyAcute Lymphoblastic Leukemia TreatmentChemotherapy Dose-limiting ToxicityChemotherapy-related ToxicityRefractory Acute Lymphoblastic LeukemiaRefractory LeukemiaRelapsed Acute Lymphoblastic LeukemiaRelapsed Leukemia
Abstract Purpose: Treatment failure from drug resistance is the primary reason for relapse in acute lymphoblastic leukemia (ALL). Improving outcomes by targeting mechanisms of drug resistance is a potential solution. Patients and Methods: We report results investigating the epigenetic modulators decitabine and vorinostat with vincristine, dexamethasone, mitoxantrone, and PEG-asparaginase for pediatric patients with relapsed or refractory B-cell ALL (B-ALL). Twenty-three patients, median age 12 years (range, 1–21) were treated in this trial. Results: The most common grade 3–4 toxicities included hypokalemia (65%), anemia (78%), febrile neutropenia (57%), hypophosphatemia (43%), leukopenia (61%), hyperbilirubinemia (39%), thrombocytopenia (87%), neutropenia (91%), and hypocalcemia (39%). Three subjects experienced dose-limiting toxicities, which included cholestasis, steatosis, and hyperbilirubinemia (n = 1); seizure, somnolence, and delirium (n = 1); and pneumonitis, hypoxia, and hyperbilirubinemia (n = 1). Infectious complications were common with 17 of 23 (74%) subjects experiencing grade ≥3 infections including invasive fungal infections in 35% (8/23). Nine subjects (39%) achieved a complete response (CR + CR without platelet recovery + CR without neutrophil recovery) and five had stable disease (22%). Nine (39%) subjects were not evaluable for response, primarily due to treatment-related toxicities. Correlative pharmacodynamics demonstrated potent in vivo modulation of epigenetic marks, and modulation of biologic pathways associated with functional antileukemic effects. Conclusions: Despite encouraging response rates and pharmacodynamics, the combination of decitabine and vorinostat on this intensive chemotherapy backbone was determined not feasible in B-ALL due to the high incidence of significant infectious toxicities. This study is registered at http://www.clinicaltrials.gov as NCT01483690.
28
EBSeq: an empirical Bayes hierarchical model for inference in RNA-seq experiments
Ning Leng, John A. Dawson, James A. Thomson et al. · Bioinformatics · 2013 · 1.4K citations · Full text
Gesche Tallen, Richard Ratei, Georg Mann et al. · Journal of Clinical Oncology · 2010 · 315 citations
Medicine, Oncology, Chemotherapy +16
Xabier Agirre, Amaia Vilas‐Zornoza, Antonio Jiménez‐Velasco et al. · Cancer Research · 2009 · 301 citations
Hagen Graf Einsiedel, Arend von Stackelberg, R. Hartmann et al. · Journal of Clinical Oncology · 2005 · 286 citations · Full text
Medicine, Hematology, Oncology +17